Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
What to know about MIT professor Nuno Loureiro and the investigation into his shooting - 2Rescuers again fail to free whale stranded on Germany's Baltic coast
- 3Some gifted dogs can learn new toy names by eavesdropping on owners
- 46 Well known Ladies' Fragrances On the planet
- 5How Mars 'punches above its weight' to influence Earth's climate
- Finding China: Four Urban areas for a Remarkable Excursion
- Congo declares its latest Ebola outbreak over, after 43 deaths
- Cyber Monday 2025: Save over 70% on HBO Max with this Prime Video streaming deal
- Instructions to Perceive and Grasp the Early Side effects of Cellular breakdown in the lungs
- Brazil passes anti-gang law allowing seized crypto to fund security forces
- The Following Huge Thing: 5 Progressive Tech New businesses
- Sexual violence part of 'everyday life' in parts of Sudan, charity says
- RFK Jr.'s handpicked vaccine panel just voted to stop recommending hepatitis B shots for all newborns. Why experts object.
- Earthquake in Indonesia kills at least 1 person and sets off small tsunami
